Bristol Myers Squibb
Search results
Celgene is a biopharmaceutical company that makes cancer and immunology drugs, such as Revlimid and Abraxane. It was founded in 1986 and became a subsidiary of Bristol Myers Squibb in 2019 after several acquisitions and collaborations.
Nov 20, 2019 · Bristol-Myers Squibb completed its merger with Celgene in November 2019, creating a leading biopharmaceutical company with diverse and promising pipelines. The transaction involved a stock-and-cash deal, a divestiture of OTEZLA, and an accelerated share repurchase program.
Jan 3, 2019 · Bristol-Myers Squibb and Celgene announce a cash and stock merger with an equity value of $74 billion. The combined company will create a leading biopharma company with complementary portfolios in oncology, immunology, inflammation and cardiovascular disease.
BMS is a leading biopharmaceutical company with a pipeline of differentiated research platforms across various therapeutic areas. Learn more about BMS's science, ESG report, careers, investors and clinical trials.
Jan 4, 2019 · Bristol-Myers Squibb Co <BMY.N> said on Thursday it would buy Celgene Corp <CELG.O> for about $74 billion, combining two of the world's largest cancer drug businesses in the biggest...
Jan 3, 2019 · Bristol-Myers Squibb, the US drugmaker, has struck one of the largest pharmaceutical deals in history, agreeing to buy Celgene in a cash-and-stock deal valuing the rival drugmaker at roughly...
Aug 1, 2022 · Catherine Owen, senior vice president of major markets at BMS, shares her insights on the merger of two pharma giants and the launch of two CAR-T cell therapies. Learn how BMS has managed the cultural, financial and operational aspects of the integration and the impact of the pandemic.
